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Abstract
Background: Despite the high frequency with which adverse drug events (ADEs) occur in outpatient settings,
detailed information regarding these events remains limited. Anticoagulant drugs are associated with increased
safety concerns and are commonly involved in outpatient ADEs. We therefore sought to evaluate ambulatory
anticoagulation ADEs and the patient population in which they occurred within the Duke University Health System
(Durham, NC, USA).
Methods: A retrospective chart review of ambulatory warfarin-related ADEs was conducted. An automated trigger
surveillance system identified eligible events in ambulatory patients admitted with an International Normalized
Ratio (INR) >3 and administration of vitamin K. Event and patient characteristics were evaluated, and quality/
process improvement strategies for ambulatory anticoagulation management are described.
Results: A total of 169 events in 167 patients were identified from December 1, 2006-June 30, 2008 and included
in the study. A median supratherapeutic INR of 6.1 was noted, and roughly half of all events (52.1%) were
associated with a bleed. Nearly 74% of events resulted in a need for fresh frozen plasma; 64.8% of bleeds were
classified as major. A total of 59.2% of events were at least partially responsible for hospital admission. Median
patient age was 68 y (range 36-95 y) with 24.9% initiating therapy within 3 months prior to the event. Of events
with a prior documented patient visit (n = 157), 73.2% were seen at a Duke clinic or hospital within the previous
month. Almost 80% of these patients had anticoagulation therapy addressed, but only 60.0% had a follow-up plan
documented in the electronic note.
Conclusions: Ambulatory warfarin-related ADEs have significant patient and healthcare utilization consequences in
the form of bleeding events and associated hospital admissions. Recommendations for improvement in
anticoagulation management include use of information technology to assist monitoring and follow-up
documentation, avoid drug interactions, and engage patients in their care.
Background
Because the majority of health care is delivered in the
ambulatory care setting, the fact that adverse drug
events (ADEs) in outpatients are suspected to occur at a
greater frequency than in the inpatient setting [1-3] is a
cause for concern. Although the number of studies on
ADEs in ambulatory care has grown [3-5], the available
information on the nature of these events remains lim-
ited. Detection of ADEs varies with the methodology
used [2,6]. Also, the vagaries of outpatient settings–
where patients oversee the majority of their own daily
care and medication use, healthcare visits are periodic,
and evidence of errors may go undocumented–further
limits ADE detection. Despite the serious nature of
these events, which can potentially result in hospitaliza-
tion, permanent injury, or death, many are in fact pre-
ventable [7,8]. While commonly implicated medication
classes include cardiovascular drugs, analgesics, hypogly-
cemic agents, and anti-infectives, several recent studies
also implicate anticoagulants as a substantial source of
outpatient ADEs and ADEs leading to hospitalizations
[3,9-13].
Warfarin is an oral anticoagulant used to prevent and
treat thromboembolism, and its use has increased
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any medium, provided the original work is properly cited.substantially over time, largely because of its indication
for atrial fibrillation in an aging population [14,15]. Due
to the variable dose-response relationship of warfarin
among patients, a narrow therapeutic index, and the
potential for numerous drug and dietary interactions,
warfarin requires ongoing monitoring during therapy
[14]. Monitoring the International Normalized Ratio
(INR), a measure of warfarin’s effect on clotting factors
and the blood’s propensity to clot, is essential for main-
taining the drug within its narrow therapeutic window.
Bleeding events are a significant cause of morbidity and
mortality with warfarin therapy [7,15], and the risk of
bleeding is largely influenced by the INR value [14].
Safety issues related to anticoagulant use have recently
been reexamined by many healthcare systems in light of
the Joint Commission’s new anticoagulation National
Patient Safety Goal 3E requiring action to “reduce the
likelihood of patient harm associated with the use of
anticoagulation therapy [16].”
Given the seriousness of warfarin-related events in
outpatients, we sought to evaluate warfarin-related
ADEs and the patient population within the Duke Uni-
versity Health System (DUHS) in which they occurred.
Our primary objective was to identify the common char-
acteristics of warfarin-related ADEs in admitted ambula-
tory patients.
Methods
Setting
Duke University Hospital (DUH) is a 1019-bed, tertiary-
care teaching hospital with approximately 36,000 patient
admissions annually. DUH is part of a greater health
system where warfarin therapy is managed by a variety
of providers, including primary care clinicians, hematol-
ogists, and cardiologists, as well as anticoagulation
clinics dispersed amongst these divisions. As part of a
comprehensive medication safety program, DUH oper-
ates computerized adverse drug event surveillance
(ADE-S), an automated trigger tool that scans inpatient
clinical data records against clinical rule logic indicative
of ADEs or potential ADEs (pADEs) [6,17]. Three clini-
cal pharmacists ( ≥ 0.88) evaluate each trigger alert by
manual chart review to confirm and document adverse
event occurrence. Each event is assigned a severity score
using the DUH Severity Index [17] and a causality score
using the Naranjo algorithm [18].
Data collection and analysis
Our study group included all adult (age ≥ 18 y) DUH
admissions from December 1, 2006-June 30, 2008 for
whom outpatient warfarin usage created a bleeding risk
(supratherapeutic INR) that was mitigated by inpatient
vitamin K administration. These admitted patients were
identified using the ADE-S “vitamin K and INR >3”
trigger rule. To be included in our analysis, event caus-
ality must be ≥ 5 and event severity ≥ 3, meaning
patient harm occurred with causality scoring indicating
a “probable” or “definite” likelihood of drug involve-
ment. Warfarin administration must have occurred out-
side of the hospital. DUH admission may have been
partly due to coagulopathy. We did not include
instances in which a patient presented to the DUH
emergency department with a high INR but was not
admitted to the hospital. ADEs were defined as any
event where bleeding was noted; pADEs were defined as
all other events where a supratherapeutic INR was cor-
rected but no bleeding was documented. Instances with-
out history of warfarin administration (e.g., INR elevated
due to a disease process) or in which anticoagulation
reversal was intentional (e.g., planned procedure pend-
ing correction of the INR) were not considered ADEs or
pADEs.
Patient demographics, medical history, and hospital
v i s i td a t aw e r ec o l l e c t e df r o mt h ee l e c t r o n i ch e a l t h
record (EHR) and hospital billing system either at the
time of event review or retrospectively upon event reex-
amination. Encounter characteristics included highest
INR, last available INR prior to hospitalization, contri-
buting factors, admission reason, bleeding site, concomi-
tant use of medications with bleeding risk, use of
additional reversal agents, and hospitalization costs.
Major bleeds were classified according to published cri-
teria: fatal bleeding; intracranial, ocular, articular, or ret-
roperitoneal bleeding; surgery or angiographic
intervention to stop bleeding; a decrease in hemoglobin
levels of ≥ 2 g/dL; and transfusion of ≥ 2 units of blood
[19]. Minor bleeding included all other cases of
bleeding.
Collected patient characteristics included age, insur-
ance coverage type, indication for anticoagulation, dura-
tion of warfarin therapy, date of most recent DUHS
healthcare visit, and date of most recent DUHS health-
care visit where anticoagulation therapy was addressed
or a follow-up plan was documented. Determination of
the provider group responsible for warfarin therapy
management was not consistently available in the EHR.
Insurance type was collected to capture whether patients
without insurance experience a greater volume of
adverse events. Collection of previous healthcare
encounter information was limited to visits with dictated
notes available through the EHR. We considered antic-
oagulation therapy to be “addressed” if either an INR
was measured or a medical note mentioned warfarin
management by any provider. We defined “follow-up” as
either documented plans to adjust or maintain the war-
farin regimen or plans for follow up on INR monitoring.
Descriptive statistics were used to analyze the adverse
event and patient characteristic data (JMP 8.0, SAS,
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sum test was used to compare non-normal continuous
data. This study was approved by the Duke University
Institutional Review Board (Duke University, Durham,
NC, USA).
Results
From December 1, 2006-June 30, 2008, DUH recorded
373,402 admissions, triggering 1444 alerts in the ADE-S
system from the “vitamin K and INR >3” rule. Of these,
clinical pharmacist reviewers identified 169 outpatient
warfarin-related events in 167 patients. A total of 88
(52.1%) had documented evidence of bleeding or patient
harm and were considered ADEs; 81 (47.9%) did not
document patient harm and were considered pADEs,
although these pADEs could have resulted in bleeding
events. Two events involved overdoses of warfarin. One
of these was an intentional overdose of multiple medica-
tions. Despite an INR >10 upon admission, no bleeding
was identified; thus, this case was determined to be a
pADE. The other overdose case, in a patient with no
indication for warfarin, was accidental. The patient mis-
takenly took several days of a spouse’s warfarin because
of similarity of packaging with, and proximity to, the
patient’s medications. Unfortunately, this patient, with
an INR of 3.2, suffered a retroperitoneal hemorrhage
requiring multiple red blood cell transfusions and hospi-
tal admission.
Event characteristics
Of all ADEs and pADEs, the median highest INR was 6.1
(range 3.1-10.0) (Table 1). The upper limit reportable by
the laboratory is an INR of 10. One quarter of events (42/
169, 24.9%) involved INRs ≥ 10. A total of 58 (34.3%) of
all events had previous INRs electronically available
within the previous 2 weeks. Of these, only 39.6% (23/58)
were within the generally accepted therapeutic range of
2.0-3.5. Only a third of events (58/169, 34.3%) had expli-
cit documentation of potential contributing factors such
as dietary issues (e.g. poor oral intake, diarrhea, vitamin
K deficiency), incorrect dosing (e.g. wrong drug
dispensed, patient non-compliance), and monitoring (e.g.
poor follow-up by either the provider or patient). How-
ever, nearly half of these contributing factors (25/58,
43.1%) were due to drug-drug interactions, mainly anti-
biotics (Table 1). The antibiotics most frequently impli-
c a t e di n2 4e v e n t si n c l u d ec i p r o f l o x a c i n( n=5 ) ,
amoxicillin/clavulanate (n = 4), moxifloxacin (n = 3), and
trimethoprim/sulfamethoxazole (n = 2).
Bleeding occurred in just over half of all identified
events (88/169, 52.1%). The most common bleeding
sites were gastrointestinal (42/88, 47.7%), intracranial
hemorrhage (10/88, 11.4%), hematuria (7/88, 8.0%), and
hemoptysis (7/88, 8.0%) (Table 2). Eighty-two of these
bleeding incidents were at least partially responsible for
the inpatient admission. A substantial proportion of
bleeds required red blood cell transfusions (51.1%) and
fresh frozen plasma (73.9%) as an additional reversal
agent. Major bleeding was evident in more than
two-thirds of bleeding events (57/88, 64.8%), with the
majority due to gastrointestinal bleeding (33/57, 57.9%),
intracranial hemorrhage (10/57, 17.5%) and hematoma
(4/57, 7.0%). Four patients with major bleeding required
administration of recombinant factor VIIa to assist in
coagulation. Concomitant use of medications with risk
of bleeding was documented in 51 (51/88, 58%) bleeding
events, with aspirin being the most prevalent (46/88,
52.3%) (Table 2).
A supratherapeutic INR and/or bleeding incident was
either partially or wholly responsible for inpatient
admission in 100 (59.2%) outpatient events. These
admissions were characterized by a median length of
stay (LOS) of 4.8 days (range 0.6-82.7 d), with an asso-
ciated median hospital cost of $10,419 (range $916-
$170,302) per visit. Cost is based on hospital expenses,
rather than patient charges or revenue. When subdi-
vided based on whether the patient bled, the median
LOS for patients who experienced bleeding was, as
expected, significantly longer than for patients without
bleeding (LOS 5.3 d [range 0.8-82.7 d] for patients with
bleeding; LOS 1.9 d [range 0.7-13.6 d] for patients with-
out bleeding; p < 0.0001). Patients with bleeding also
Table 1 Event Characteristics
Characteristic Total events
(n = 169)
ADEs
(n = 88)
pADEs
(n = 81)
Highest INR, median (range)* 6.1 (3.1-10.0) 5.1 (3.1-10.0) 7.1 (3.3-10.0)
Known contributors, No. (%) 58 (34.3%) 29 (33.0%) 29 (35.8%)
Drug-drug interactions 25 12 13
Dietary interaction 30 13 17
Monitoring issue 8 6 2
Dosing issue 6 2 4
*The upper reportable limit of INR laboratory measurement is 10; INRs above this value are reported as >10.
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patients without bleeding ($11,526 [range $2,451-
$170,302] vs. $2,813 [range $916-$23,582]; p < 0.0001).
Patient characteristics
The median age of patients involved in ambulatory
anticoagulation ADEs and pADEs was 68 y (range 36 y-
95 y) (Table 3). All patients were insured, with 78.1%
having either private insurance or a combination of
Medicare and private insurance (Table 3). Atrial fibrilla-
tion (54.4%), deep vein thrombosis (27.2%), valve repla-
cement (13.6%), and pulmonary embolism (15.4%) were
the most common indications for anticoagulation. Dura-
tion of warfarin anticoagulation could only be deter-
mined in 68.6% of events (116/169); more than half
(53.4%, 62/116) of these involved patients on warfarin
for >12 months, with 36.2% (42/116) newly started on
warfarin ≤ 3 months prior to the event (Table 3).
Nearly all events (157/169, 92.9%) involved patients
with at least 1 prior healthcare visit, as evidenced by an
inpatient or outpatient provider note in the EHR. The
median time since previous encounter was 15.8 days
(range 0.6-2994.7 d), with the majority of previous
encounters being ambulatory visits (114/157, 72.6%).
Nearly three-fourths of events (115/157, 73.2%) involved
patients who were last seen by a DUHS provider in the
previous month; 26.1% (30/115) were recently hospita-
lized. All hospitalized patients had their anticoagulation
therapy addressed, as evidenced by INR monitoring and/
or documentation of management in the discharge
summary. However, only 76.7% of these hospitalizations
had anticoagulation follow-up plans documented in the
discharge summary. Among patients whose last encoun-
ter occurred in the ambulatory care setting in the pre-
vious month (85/115, 73.9%), only 56.5% had
documented evidence that anticoagulation therapy was
addressed, and only 45.9% had documented follow-up
plans.
Since we were unable to confirm whether the last seen
provider was responsible for monitoring warfarin ther-
apy, we also evaluated whether these assessments took
place at any visit in the past month. Of 115 events in
which a patient had a documented visit note in the EHR
within the past month, 90 (78.3%) addressed anticoagu-
lation therapy and 69 (60.0%) had follow-up plans noted
in at least one healthcare visit note. Not all medical ser-
vices share primary responsibility for anticoagulation
therapy management. However, among the services
noted as failing to address anticoagulation therapy in
the previous month, cardiology, hematology, and medi-
cine, which often oversee warfarin therapy management
based on corresponding indications, accounted for a
total of 32.0% (8/25).
Discussion
In this study, we used computerized ADE surveillance of
hospitalized patients, coupled with targeted chart review,
to identify 169 warfarin-related ADEs and pADEs that
occurred in the DUHS ambulatory environment. Our
descriptive analysis demonstrates that anticoagulant
ambulatory events have a significant clinical impact on
patients and contribute significantly to healthcare costs.
Although the rate of ADEs can vary depending on
data collection methodology, several studies have
reported that anticoagulants, including warfarin, are
among the medication classes most frequently associated
with ambulatory ADEs and ADEs requiring hospital
admission [3,9-13]. Using a computer-based event detec-
tion application, Jha and colleagues identified hospital
admissions due to ADEs. Anticoagulants were impli-
cated in 9% (7/76) of these ADEs; however, warfarin
was the most common individual agent identified in all
events [11]. In a review of elderly patients by Gurwitz et
al, anticoagulants accounted for 8% of ambulatory
ADEs, the fifth most common medication class involved
in events [10]. As part of the National Electronic Injury
Surveillance System-All Injury Program, trained coders
from nine participating hospitals identified ADEs noted
in emergency department records. Anticoagulants were
associated with 4.7% of ED visits; more strikingly, they
were the third leading cause (15.4%) of ADEs resulting
in hospitalization. Together, warfarin and insulin
accounted for 16% of all outpatient ADEs and 33% of
outpatient ADEs in patients aged ≥ 50 years [9].
Table 2 Bleeding characteristics (n = 88)
Characteristic ADEs
No. (%)
Use of medications with increased bleeding risk 51 (58.0%)
Aspirin 46
Enoxaparin 6
Clopidogrel 3
Ibuprofen 4
Heparin 1
> 2 of above 9
Use of fresh frozen plasma 65 (73.9%)
Major bleeds 57 (64.8%)
Location of major and minor bleeds*
Intracranial hemorrhage 10
Gastrointestinal 42
Hematoma 6
Hemoptysis 7
Retroperitoneal 3
Intra-articular 1
Wound/incision site 6
Other 18
*An event may have more than one location of bleeding.
Long et al. Thrombosis Journal 2010, 8:5
http://www.thrombosisjournal.com/content/8/1/5
Page 4 of 8Not only is warfarin involved in a large proportion of
ambulatory ADEs, but its effect on patient outcomes is
also substantial. In our study, the median highest INR at
the time of the event was 6.1, and more than half
(52.1%) of these cases resulted in a bleeding event. The
majority (64.8%) were defined as major bleeds, with
intracranial hemorrhages accounting for 17.5% of these.
The intensity of warfarin therapy is known to be
strongly associated with bleeding risk, and an INR ≥ 4.5
is the single greatest risk factor for bleeding [14].
Patients and health systems are also affected by hospi-
tal admissions stemming from these warfarin-related
events. Due to the nature of our surveillance system, all
events were identified in patients already admitted to
the hospital for reasons that could include coagulopathy,
other diagnoses, or both. Interestingly, more than half
(59.2%) of admissions were due at least in part to cor-
rection of coagulopathy. Budnitz et al reported on
ambulatory ADEs identified via surveillance of ED
records in geriatric patients. Among warfarin-related
ADEs, not only did 73% result in bleeds, but 44.2% of
cases required hospitalization [13]. Other studies have
noted the propensity for warfarin-related ADEs to lead
to hospitalization [9,11].
Such potentially avoidable hospitalizations can be very
costly to the healthcare system. In our study, for each
admission due to coagulopathy regardless of bleeding,
the median cost of care was $10,419, with a median
LOS of 4.8 d. Of course, other diagnoses and complicat-
ing factors may have influenced both cost of care and
LOS, but a broad generalization suggests that if the
ADEs and pADEs had not occurred, more than half of
the hospital admissions could have been avoided, saving
the hospital and payers nearly $1.7 million over 19
months. Moreover, 73.9% of bleeding events required
fresh frozen plasma to rapidly reverse the INR, and
Table 3 Patient characteristics
Characteristic Total events
(n = 169)
ADEs
(n = 88)
Potential ADEs
(n = 81)
Age, mean +/- SD 68.1 +/- 13.2
(range 36-95)
69.5 +/- 13.5
(range 37-90)
66.6 +/- 12.8
(range 36-95)
Insurance, No. (%)
Private 32 (18.9%) 19 (21.6%) 13 (16.0%)
Private/Medicare 100 (59.2%) 52 (59.1%) 48 (59.3%)
Private/Medicaid 3 (1.8%) 0 3 (3.7%)
Medicare 12 (7.1%) 7 (8.0%) 5 (6.2%)
Medicare/Medicaid 14 (8.3%) 7 (8.0%) 7 (8.6%)
Medicaid 8 (4.7%) 3 (3.4%) 5 (6.2%)
Indication, No. (%)
Atrial fibrillation 92 (54.4%) 51 41
Deep vein thrombosis 46 (27.2%) 19 27
Pulmonary embolism 26 (15.4%) 13 13
Stroke 23 (13.6%) 15 8
Valve replacement 23 (13.6%) 11 12
Hypercoagulable 11 (6.5%) 3 8
Other 10 (5.9%) 4 6
Indeterminate 1 (0.6%) 0 1
None 1 (0.6%) 1 0
Duration of warfarin therapy, No. (%)
<1 mo 25 (14.8) 12 (13.6) 13 (16.0)
1-3 mos 17 (10.1) 8 (9.1) 9 (11.1)
4-6 mos 9 (5.3) 3 (3.4) 6 (7.4)
7-12 mos 11 (6.5) 8 (9.1) 3 (3.7)
1-5 y 29 (17.2) 13 (14.8) 16 (19.8)
> 5 y 25 (14.8) 15 (17.0) 10 (12.3)
Indeterminate 52 (30.8) 28 (31.8) 24 (29.6)
No prescribed warfarin 1 (0.6) 1 (1.1) 0
Seen at Duke clinic or hospital within 30 d, No. (%)* 115 (73.2%) 52 (65.0%) 63 (81.8%)
Anticoag. therapy addressed within 30 d, No. (%)* 90 (57.3%) 43 (53.8%) 47 (61.0%)
*Denominator limited to events with a prior encounter note present in the EHR:
Total events = 157, ADEs = 80, pADE = 77.
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colleagues noted 76 ambulatory ADEs led to hospital
admissions totalling 738 patient days, with a median 5-
day LOS and an average cost of $16,177 per visit [11].
Interestingly, 24 patients in our study experienced a
total of 28 additional warfarin-related ADEs identified
by ADE-S either before or subsequent to the study per-
iod. Ten of these events occurred within 6 months fol-
lowing the study. These potentially avoidable warfarin-
related events result in significant healthcare costs to
the DUHS, and such problems are likely to be found in
other organizations as well.
Quality improvements in ambulatory care can be
accomplished by strengthening the information technol-
ogy (IT) infrastructure [20]. The main process areas that
should be targeted include prescribing and monitoring,
since errors in these processes respectively account for
41.0%-64.7% and 26.0%-72.7% of preventable ambulatory
ADEs [3,10,21]. For warfarin-related events in this study
where contributing factors could be identified retrospec-
tively, we found drug interactions, particularly between
antibiotics and warfarin, to be most common. Antibio-
tics are known to contribute to deviations in INR; thus,
initiation of such medications in outpatients without
close monitoring may result in supratherapeutic INRs
and possible harmful outcomes. Ambulatory e-prescrib-
ing with drug interaction checking can help reduce
medication errors [22,23]. In addition, ambulatory EHRs
can have further additive benefits by providing electroni-
cally-available provider notes and medication reconcilia-
tion. In this study, 73.2% of the events for which a prior
record existed in our EHR occurred in patients seen at
an inpatient or outpatient DUHS healthcare visit within
the previous 4 weeks; however, 40.0% did not have a
documented follow-up plan within that same period.
EHRs can help bridge the communication gap during
transitions in care and assist providers with decision-
making and lab test follow-up [20]. This is extremely
important not only for warfarin use, where monitoring
is critical, but also applies broadly to clinical care given
the segmented nature of health care.
However, the impact of quality improvement strategies
for the safe management of warfarin therapy may be
most felt in terms of fostering patient empowerment
and engaging patients in the ownership of their care.
Patient nonadherence has been reported as being among
the most common drug therapy problems associated
with hospital admissions [3]. In our study, evidence of
non-compliance was limited to specific documentation
b yp r o v i d e r sa n dt h u st h et r u er a t eo fn o n a d h e r e n c ei s
likely under-reported. Furthermore, the infrastructure of
the ambulatory care environment is typically segmented
and logistically complex, with patients often forced to
seek their care from various providers or specialists,
pharmacies, and laboratories spanning multiple health
systems.
For these reasons, it is clearly essential that patients be
equipped with the knowledge and understanding of their
role in their own care. Recognizing this, the Joint Com-
mission instituted National Patient Safety Goal 13,
which encourages “...patients’ active involvement in their
own care as a patient safety strategy” [16]. Patient edu-
cation is also encouraged in the CHEST guidelines, and
at least one study reported lower warfarin-related hospi-
talizations for bleeding in patients who received educa-
tion regarding warfarin therapy [14,24].
Health portals or personal health records can also be
leveraged to encourage active patient involvement in
improving drug safety. Health portals not only provide
education via access to consumer medication and health
knowledge resources, but also allow access to patients’
medical information (e.g., displaying current medication
lists and laboratory values) [25]. Moreover, interactive
portals could permit patients to enter information, such
as INR values or medication changes, obtained from
various facilities, to maintain an accurate, up-to-date
health record [25,26]. The full potential of portals has
yet to be explored, but thus far, patients report satisfac-
tion with using many of their features [26-28].
Though not suitable for all patients, home monitoring
of INR using point-of-care testing (POCT) also remains
av i a b l eo p t i o nf o rp a t i e n t involvement [29-32].
Although 73.2% of our events were reported in patients
who had a healthcare visit within the previous month,
INR elevations still occurred. Deviations in warfarin
control may be due to events occurring between health-
care visits that the patient may be first to recognize and
mitigate if given proper knowledge and tools. Further-
more, use of POCT has shown reductions in bleeding
and thromboembolic complications [33].
Additional improvements in warfarin dosing may also
be made possible by the clinical application of pharma-
cogenomic guided therapy [34-36]. Single nucleotide
polymorphisms (SNPs) in the CYP2C9 and VKORC1
genes have been associated with a wide variability in
patient response to warfarin dosing and a potentially
greater risk for adverse events [34,36]. A randomized
controlled trial of the clinical safety and efficacy of gen-
otype-guided warfarin dosing (the European Genetics of
Anticoagulant Therapy Trial [EU-PACT]) is currently
under way [37].
Our study has several limitations that should be
acknowledged. We only detected events in patients
admitted to the hospital and did not capture warfarin-
related events requiring visits to the ED only, urgent
care, or other outpatient facilities. In addition, we did
not capture warfarin-related events for which the INR
value was within the therapeutic range due to the
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Oake et al noted that half of all bleeding complications
in outpatients occurred despite an INR value within
therapeutic range [38]. Given our retrospective review,
we could only confirm documentation of follow-up
plans, but it remains unknown whether the plan was
actually discussed explicitly with the patient, or if a plan
was verbally communicated and not documented.
Conclusions
Ambulatory warfarin-related ADEs have significant
effects on both patient outcomes and healthcare costs,
as evidenced by bleeding outcomes, hospitalizations, and
transfusion of blood products. The majority of patients
we examined had recently received health care within
the DUHS, yet documentation of warfarin follow-up
plans was lacking, and warfarin-antibiotic drug interac-
tions were noted. The use of IT to assist in monitoring
and follow-up documentation (ambulatory EHRs), for
avoidance of drug interactions (electronic prescribing),
and to engage patients in their care (personal health
portals) should be explored in order to provide safer
care for patients receiving warfarin therapy.
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